Aflac reported a decline in net earnings and total revenues for Q4 2025 compared to the prior year, primarily due to lower net investment gains. However, adjusted earnings per diluted share saw a slight increase, and the company highlighted strong sales growth in Japan and stable premium growth in the U.S., alongside a significant increase in its quarterly dividend.
Adjusted earnings per diluted share increased 0.6% to $1.57 in Q4 2025.
positiveAflac Japan's new annualized premium sales increased 15.7% in Q4 2025, driven by sales of the Miraito cancer insurance product.
positiveAflac U.S. net earned premiums increased 4.0% in Q4 2025, reflecting improved sales and strong persistency.
positiveThe quarterly dividend was increased by 5.2% to $0.61 per share.
positiveTotal revenues decreased 9.9% to $4.9 billion in Q4 2025 compared to $5.4 billion in Q4 2024.
negativeNet earnings decreased 27.5% to $1.4 billion in Q4 2025 compared to $1.9 billion in Q4 2024, largely due to lower net investment gains.
negativeAdjusted earnings decreased 5.4% to $818 million in Q4 2025 compared to $865 million in Q4 2024.
negativeAflac Japan's net earned premiums decreased 3.0% in dollar terms to $1.6 billion in Q4 2025.
negativeAflac U.S. pretax adjusted earnings decreased 9.1% to $300 million in Q4 2025.
negativeShareholders' equity included an unrealized foreign currency translation loss of $4.8 billion at December 31, 2025.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total |
|---|---|---|---|---|
AFLAC JAPAN | N/A | — | — | — |
AFLAC U.S.A. | N/A | — | — | — |
CORPORATE AND OTHER | N/A | — | — | — |
| Total Revenue | $0.00M | — | — | 100.0% |
Segment performance shows business unit health and growth drivers.
Aflac delivered solid earnings for the quarter and the year, reflecting focused efforts to execute on strategy.
Pleased with Aflac Japan’s quarterly sales increase of 15.7% and annual sales increase of 16.0%, benefiting from cancer insurance product sales.
Encouraged by Aflac U.S.'s ability to add $1.6 billion in new sales for the year and maintain strong persistency of 79.2%.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.